- Home
- GNTA vs CNTB Comparison
GNTA vs CNTB Comparison
Compare GNTA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | CNTB |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 128.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNTA | CNTB |
|---|---|---|
| Price | $1.42 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 122.9K | ★ 314.4K |
| Earning Date | 03-30-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $762,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $38,289.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.28 | $0.51 |
| 52 Week High | $10.00 | $3.28 |
Technical Indicators
Market Signals| Indicator | GNTA | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 48.07 |
| Support Level | $1.28 | $2.03 |
| Resistance Level | $1.77 | $2.38 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 22.78 | 36.36 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.